Clinical Trial Update: 2 Year Study to Evaluate the Effects of GPI 1485 on [123I]b-CIT/SPECTScanning and Clinical Efficacy in Patients With PD [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating GPI-1485 in Parkinson's disease, including imaging with [123I]β-CIT/SPECT, has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• GPI-1485

Snippet

Sponsor: Eisai Inc. | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED